0 -0.000874890638670148 0 0.000437445319335151 -0.000109361329833671 0.00185914260717412 -0.00820209973753281 -0.00820209973753281
Sign Up Today X
Thanks for submitting the form.
Stockreport

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Among bigwigs, Gilead Sciences, Inc . GILD and GSK plc GSK had a few regulatory updates. Recap of the Week's Most Important Stories Updates From Gilead Sciences Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The designation is based on results from the ES-SCLC cohort of the mid-stage study TROPiCS-03 study. Trodelvy demonstrated promising antitumor activity in both platinum-resistant and platinum-sensitive disease, and the safety profile was consistent with the previous studies. Gilead plans to initiate a phase III study in this patient population. Concurrently, GILD announced entering a strategic collaboration with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets. Per t [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Among bigwigs, Gilead Sciences, Inc . GILD and GSK plc GSK had a few regulatory updates. Recap of the Week's Most Important Stories Updates From Gilead Sciences Gilead Sciences announced that the FDA has granted Breakthrough Therapy Designation to breast cancer drug Trodelvy (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy. The designation is based on results from the ES-SCLC cohort of the mid-stage study TROPiCS-03 study. Trodelvy demonstrated promising antitumor activity in both platinum-resistant and platinum-sensitive disease, and the safety profile was consistent with the previous studies. Gilead plans to initiate a phase III study in this patient population. Concurrently, GILD announced entering a strategic collaboration with Terray Therapeutics to discover and develop novel, small molecule therapies across multiple targets. Per t [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS